SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019)
Por:
Majem, M, Garcia-Martinez, E, Martinez, M, Munoz-Couselo, E, Rodriguez-Abreu, D, Alvarez, R, Arance, A, Berrocal, A, de la Cruz-Merino, L, Lopez-Martin, JA
Publicada:
1 feb 2020
Resumen:
The use of immune checkpoint inhibitors has emerged as an effective treatment option for patients with several tumor types. By increasing the activity of the immune system, they can induce inflammatory side effects, which are often termed immune-related adverse events. These are pathophysiologically unique toxicities, compared with those from other anticancer therapies. In addition, the spectrum of the target organs is very broad. Immune-inflammatory adverse events can be life threatening. Prompt diagnosis and pharmacological intervention are instrumental to avoid progression to severe manifestations. Consequently, clinicians require new skills to successfully diagnose and manage these events. These SEOM guidelines have been developed with the consensus of ten medical oncologists. Relevant studies published in peer-review journals were used for the guideline elaboration. The Infectious Diseases Society of America grading system was used to assign levels of evidence and grades of recommendation.
Filiaciones:
Majem, M:
Hosp Santa Creu & Sant Pau, Dept Med Oncol, C Sant Antoni Maria Claret 167, E-08025 Barcelona, Spain
GeTICA, Spanish Grp Canc Immuno Biotherapy, Madrid, Spain
Garcia-Martinez, E:
Hosp Univ Morales Meseguer, Dept Med Oncol & Hematol, Murcia, Spain
GeTICA, Spanish Grp Canc Immuno Biotherapy, Madrid, Spain
Martinez, M:
Hosp Mar, Dept Med Oncol, Barcelona, Spain
Munoz-Couselo, E:
Vall Hebron Inst Oncol VHIO, Vall Hebron Hosp, Dept Med Oncol, Melanoma & Other Skin Tumors Unit, Barcelona, Spain
Rodriguez-Abreu, D:
CHU Insular Materno Infantil Gran Canaria, Dept Med Oncol, Las Palmas Gran Canaria, Spain
GeTICA, Spanish Grp Canc Immuno Biotherapy, Madrid, Spain
Alvarez, R:
Hosp Virgen Salud, Dept Med Oncol, Toledo, Spain
Arance, A:
Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain
GeTICA, Spanish Grp Canc Immuno Biotherapy, Madrid, Spain
Berrocal, A:
Consorcio Hosp Gen Univ Valencia, Dept Med Oncol, Valencia, Spain
de la Cruz-Merino, L:
Hosp Univ Virgen Macarena, Clin Oncol Dept, Seville, Spain
Univ Seville, Med Dept, Seville, Spain
GeTICA, Spanish Grp Canc Immuno Biotherapy, Madrid, Spain
Lopez-Martin, JA:
Hosp Univ, Dept Med Oncol, 12 Octubre, Madrid, Spain
Inst Invest Sanitaria Hosp, Clin & Translat Oncol, 12 Octubre, Madrid, Spain
GeTICA, Spanish Grp Canc Immuno Biotherapy, Madrid, Spain
Hybrid Gold
|